Title: Dasatinib
CAS Registry Number: 302962-49-8
CAS Name: N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
Manufacturers' Codes: BMS-354825
Molecular Formula: C22H26ClN7O2S
Molecular Weight: 488.01
Percent Composition: C 54.15%, H 5.37%, Cl 7.26%, N 20.09%, O 6.56%, S 6.57%
Literature References: Orally bioactive, ATP-competitive dual inhibitor of Src and Abl kinases. Prepn: J. Das et al., WO 0062778; eidem US 6596746 (2000, 2003 both to Bristol-Myers Squibb); and Src/Abl kinase inhibition study: L. J. Lombardo et al., J. Med. Chem. 47, 6658 (2004). In vivo evaluation vs imatinib-resistant mutants in chronic myeloid leukemia: N. P. Shah et al., Science 305, 399 (2004). Mechanism of action study: M. R. Burgess et al., Proc. Natl. Acad. Sci. USA 102, 3395 (2005). Review of therapeutic potential in chronic myeloid leukemia: T. O'Hare et al., Curr. Opin. Genet. Dev. 16, 92-99 (2006).
Properties: mp 279-280°.
Melting point: mp 279-280°
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.
Datiscetin Daucol Daunorubicin Dauricine DBHBT

Systematic (IUPAC) name
carboxamide monohydrate
Clinical data
Trade names Sprycel
AHFS/Drugs.com monograph
MedlinePlus a607063
Licence data EMA:Link, US FDA:link
Pregnancy cat. D (AU) D (US)
Legal status -only (US)
Routes Oral
Pharmacokinetic data
Protein binding 96%
Metabolism Hepatic
Half-life 1.3 to 5 hours
Excretion Faecal (85%), renal (4%)
CAS number 302962-49-8 YesY
ATC code L01XE06
PubChem CID 3062316
DrugBank DB01254
ChemSpider 2323020 YesY
KEGG D03658 N
ChEBI CHEBI:49375 YesY
Chemical data
Formula C22H26ClN7O2S 
Mol. mass 488.01 g/mol
 N (what is this?)  (verify)

Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral multi- BCR/Abl and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML)[1] and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.

The drug is named after one of the inventor chemists, Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.[2]